Evidence map›Paper›PMID 25244877›Full record

Observational studyPuerto Rico health sciences journal2014

Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.

Isa I Valentín, Giselle Rivera, Mariely Nieves-Plaza, Iadelisse Cruz, Jessica Y Renta, Carmen L Cadilla, Juan F Feliu, Richard L Seip, Gualberto Ruaño, Jorge Duconge

Registry-linked trialOpen access · greenAbstract readObservational Study
PubMed Full text at PMC
In one paragraph

Observational study in Puerto Rico health sciences journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01318057 (Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01318057 completednot on this map

Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.

TypeobservationalSponsorUniversity of Puerto RicoRan2011 to 2014Enrolled350ConditionsAtrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Antiphospholipid Syndrome
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Drug metabolism and personalized therapy · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Isa I Valentín
Giselle Rivera
Mariely Nieves-Plaza
Iadelisse Cruz
Jessica Y Renta
Carmen L Cadilla
Juan F Feliu
Richard L Seip
Gualberto Ruaño
Jorge Duconge
Hartford Hospital · USVA Caribbean Healthcare System · PRClinical Research Puerto Rico · PRUniversity of Puerto Rico, Medical Sciences Campus · PR

Funding

SUPPLEMENT FOR RENOVATION OF ANIMAL FACILITIES AT INSTITUTE OF NEUROBIOLOGYG12RR003051 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ESPINO, ANA M · 1986 to 2011
$28.1M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LUCIANO, CARLOS A., NOBOA, CARIAMARIE · 2012 to 2018
$23.2M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
TRCLU54RR026139 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ZORRILLA, CARMEN D · 2010 to 2011
$8.4M
Pharmacogenetics of Warfarin in Puerto Rican Patients using a Physiogenomics ApprSC2HL110393 · NHLBI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI DUCONGE, JORGE · 2011 to 2013
$332k
NCI NIH HHS SC2HL110393NCRR NIH HHS 2G12-RR003051NCRR NIH HHS G12 RR003051NCRR NIH HHS U54 RR026139NHLBI NIH HHS SC2 HL110393NIMHD NIH HHS G12 MD007600NIMHD NIH HHS U54 MD007587
6 · The paper itself

Abstract

objectiveThis study was intended to determine the incidence rate of warfarin-related adverse events (e.g., bleeding) in Puerto Ricans and whether a genetic association between warfarin pharmacogenes and any of these adverse events was observed over the initiation period (i.e., the first 90 days of therapy).

methodsWe conducted an observational, retrospective cohort study of pharmacogenetic association in 122 warfarin-treated, male, Puerto Rican patients (69.9 +/- 9.6 years) from the Veterans Affair Caribbean Healthcare System (VACHS) who consented to participate. Genotyping was performed using the CYP2C9 and VKORC1 assays by Luminex. Event-free survival curves were estimated using the Kaplan-Meier method and analyzed by log-rank test. Cox regression models were constructed and hazard ratios (HR) calculated.

resultsCarriers of functional CYP2C9 and VKORC1 polymorphisms demonstrated a higher incidence rate of multiple adverse events (i.e., 5.2 vs. 1.0 cases per 100 patient-months; RR = 4.8, p = 0.12) than did wild types. A significant association was observed between multiple adverse events and carrier status (HR = 2.5; 95% CI: 1.0-6.3, p = 0.04). However, no significant associations between genotypes and individual outcomes over the first 90 days of therapy were found.

conclusionThe association of CYP2C9 and VKORC1 genotypes and risks for adverse events due to exposure to warfarin was examined for the first time in Puerto Ricans. Despite a lack of association with individual events in this study population, our findings revealed a potential utility of genotyping for the prevention of multiple adverse events during warfarin therapy.

Indexed as

AdultAgedAged, 80 and overAnticoagulantsCohort StudiesGenotypeHemorrhageHumansMiddle AgedPuerto RicoRetrospective StudiesWarfarinAnticoagulantsWarfarin

Identifiers

PMID25244877
PMCPMC4196861
OpenAlexW1872635366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.